A federal push to accelerate psychedelic research could soon bring new treatment options to millions of Americans who haven’t found relief from standard antidepressants and therapy. President Trump signed an executive order to speed up the research, and the FDA is fast-tracking review of three psychedelic drugs for PTSD, major depressive disorder, and treatment-resistant depression.
The human stakes are hard to overstate. Logan Curtis spent 25 years battling anxiety and depression tied to childhood abuse before ketamine treatments at a Charlotte clinic finally gave him relief. His words: “I don’t want to just exist.” Dr. Jonathan Leake, who has treated patients with ketamine for a decade, says he watches people transform over six weeks. Ketamine is currently the only legal psychedelic medicine in North Carolina. Ibogaine is also under study but carries more serious heart risks.
The key detail for Suncoast residents: states, not the federal government, will largely carry out the research and treatment. Oregon and Colorado have already legalized certain psychedelic therapies. If approvals come later this year, Florida will have its own decisions to make about access and regulation. For families who have watched a loved one struggle through every available option, that timeline matters.
What’s your take: should Florida move quickly on psychedelic therapy if the FDA gives the green light, or wait for more data first?
